RWE in Pharma: Interview with Clare Hague, Janssen’s Therapy Area Market Access Leader for Hematology
December 3, 2021
On The Evidence Base’s RWE in Pharma, Claire Hague talks about the current impact of real-world data and evidence (RWD/RWE), a route to increased trust in RWE, and her role at Janssen. Hague explains how using RWD and RWE to improve COVID-19 management strategies highlighted its importance. Finally, she discusses the upcoming US FDA RWE Framework.
According to Hague, “Elevating the role that RWE plays in enhancing traditional regulatory data will probably result in a renewed focus on further building RWE capabilities and increasing investment in RWE studies. Pharma companies will need to plan ahead to ensure they design RWE studies thoroughly to support their products and have the relevant in-house expertise to oversee the studies, in collaboration with external data partners.“
Read her entire interview by clicking here.
(Source: The Evidence Base, November 26th, 2021)